These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 22027240)

  • 1. Soluble receptor activator of nuclear factor κB ligand/osteoprotegerin ratio is increased in systemic lupus erythematosus patients.
    Carmona-Fernandes D; Santos MJ; Perpétuo IP; Fonseca JE; Canhão H
    Arthritis Res Ther; 2011; 13(5):R175. PubMed ID: 22027240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RANKL and OPG gene polymorphisms: associations with vertebral fractures and bone mineral density in premenopausal systemic lupus erythematosus.
    Bonfá AC; Seguro LP; Caparbo V; Bonfá E; Pereira RM
    Osteoporos Int; 2015 May; 26(5):1563-71. PubMed ID: 25609157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum RANKL, osteoprotegerin (OPG) and RANKL/OPG ratio in children with systemic lupus erythematosus.
    Ali R; Hammad A; El-Nahrery E; Hamdy N; Elhawary AK; Eid R
    Lupus; 2019 Sep; 28(10):1233-1242. PubMed ID: 31403902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating osteoprotegerin and soluble RANK ligand in systemic sclerosis.
    Dovio A; Data V; Carignola R; Calzolari G; Vitetta R; Ventura M; Saba L; Severino A; Angeli A
    J Rheumatol; 2008 Nov; 35(11):2206-13. PubMed ID: 18843778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. sRANKL/osteoprotegerin complex and biochemical markers in a cohort of male and female hemodialysis patients.
    Doumouchtsis KK; Kostakis AI; Doumouchtsis SK; Tziamalis MP; Tsigris C; Kostaki MA; Perrea DN
    J Endocrinol Invest; 2007 Oct; 30(9):762-6. PubMed ID: 17993768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iron chelation therapy in Upper Egyptian transfusion-dependent pediatric homozygous beta-thalassemia major: impact on serum L-carnitine/free fatty acids, osteoprotegerin/the soluble receptor activator of nuclear factor-kappabeta ligand systems, and bone mineral density.
    Hamed EA; Mohamed NA; El-Metwally TH; Kamal MM
    J Pediatr Hematol Oncol; 2010 May; 32(4):267-73. PubMed ID: 20445416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum receptor activator of nuclear factor κB ligand (RANKL) levels predict biochemical recurrence in patients undergoing radical prostatectomy.
    Todenhöfer T; Hennenlotter J; Leidenberger P; Wald A; Hohneder A; Kühs U; Mischinger J; Aufderklamm S; Gakis G; Blumenstock G; Stenzl A; Schwentner C
    BJU Int; 2014 Jan; 113(1):152-9. PubMed ID: 23360112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age and gender predict OPG level and OPG/sRANKL ratio in maintenance hemodialysis patients.
    Naumnik B; Klejna K; Koc-Żórawska E; Myśliwiec M
    Adv Med Sci; 2013; 58(2):382-7. PubMed ID: 23959668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. OPG and sRANKL serum levels and incident hip fracture in postmenopausal Caucasian women in the Women's Health Initiative Observational Study.
    LaCroix AZ; Jackson RD; Aragaki A; Kooperberg C; Cauley JA; Chen Z; Leboff MS; Duggan D; Wactawski-Wende J
    Bone; 2013 Oct; 56(2):474-81. PubMed ID: 23735608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of Serum sRANKL, sRANKL/OPG Ratio, and Other Bone Turnover Markers with the Estimated 10-Year Risk of Major and Hip Osteoporotic Fractures in Rheumatoid Arthritis: A Cross-Sectional Study.
    Nava-Valdivia CA; Ponce-Guarneros JM; Saldaña-Cruz AM; Corona-Sanchez EG; Ramirez-Villafaña M; Perez-Guerrero EE; Murillo-Saich JD; Contreras-Haro B; Vazquez-Villegas ML; Gonzalez-Ponce F; Bonilla-Lara D; Jacobo-Cuevas H; Centeno-Valadez JD; Echeverria-Gonzalez G; Cerpa-Cruz S; Alcaraz-Lopez MF; Cardona-Muñoz EG; Salazar-Paramo M; Gonzalez-Lopez L; Gamez-Nava JI
    Biomed Res Int; 2021; 2021():5567666. PubMed ID: 34497849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum osteoprotegrin (OPG) and receptor activator of nuclear factor kappaB (RANKL) in healthy children and adolescents.
    Wasilewska A; Rybi-Szuminska AA; Zoch-Zwierz W
    J Pediatr Endocrinol Metab; 2009 Dec; 22(12):1099-104. PubMed ID: 20333868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) concentrations in allogeneic stem cell transplant-recipients: a role in bone loss?
    Kananen K; Volin L; Laitinen K; Ruutu T; Välimäki MJ
    Osteoporos Int; 2006; 17(5):724-30. PubMed ID: 16437190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone metabolism, osteoprotegerin, receptor activator of nuclear factor-κB ligand and selected adipose tissue hormones in girls with anorexia nervosa.
    Ostrowska Z; Ziora K; Oświęcimska J; Świętochowska E; Marek B; Kajdaniuk D; Wołkowska-Pokrywa K; Kos-Kudła B
    Endokrynol Pol; 2014; 65(1):33-9. PubMed ID: 24549600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory effect of parathyroid hormone on sRANKL-osteoprotegerin in hemodialysis patients with renal bone disease.
    Doumouchtsis K; Perrea D; Doumouchtsis S; Tziamalis M; Poulakou M; Vlachos I; Kostakis A
    Ther Apher Dial; 2009 Feb; 13(1):49-55. PubMed ID: 19379170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated serum levels of soluble receptor activator of nuclear factors-kappaB ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS).
    Kim HR; Lee SH; Kim HY
    Rheumatology (Oxford); 2006 Oct; 45(10):1197-200. PubMed ID: 16567356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selected pro-inflammatory cytokines, bone metabolism, osteoprotegerin, and receptor activator of nuclear factor-kB ligand in girls with anorexia nervosa.
    Ostrowska Z; Ziora K; Oświęcimska J; Marek B; Świętochowska E; Kajdaniuk D; Strzelczyk J; Cieślicka A; Wołkowska-Pokrywa K; Kos-Kudła B
    Endokrynol Pol; 2015; 66(4):313-21. PubMed ID: 26323468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variations along the 24-hour cycle of circulating osteoprotegerin and soluble RANKL: a rhythmometric analysis.
    Dovio A; Generali D; Tampellini M; Berruti A; Tedoldi S; Torta M; Bonardi S; Tucci M; Allevi G; Aguggini S; Bottini A; Dogliotti L; Angeli A
    Osteoporos Int; 2008 Jan; 19(1):113-7. PubMed ID: 17703272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RANKL/RANK/OPG system and bone status in females with anorexia nervosa.
    Ostrowska Z; Ziora K; Oświęcimska J; Swiętochowska E; Szapska B; Wołkowska-Pokrywa K; Dyduch A
    Bone; 2012 Jan; 50(1):156-60. PubMed ID: 22001124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selected adipose tissue hormones, bone metabolism, osteoprotegerin and receptor activator of nuclear factor-kB ligand in postmenopausal obese women.
    Ostrowska Z; Świętochowska E; Marek B; Kajdaniuk D; Tyrpień-Golder K; Wołkowska-Pokrywa K; Damasiewicz-Bodzek A; Kos-Kudła B
    Endokrynol Pol; 2014; 65(6):438-48. PubMed ID: 25554611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma levels of sRANKL and OPG are associated with atherogenic cytokines in patients with intermediate cardiovascular risk.
    Raaz-Schrauder D; Schrauder MG; Stumpf C; Lewczuk P; Kilian T; Dietel B; Garlichs CD; Schlundt C; Achenbach S; Klinghammer L
    Heart Vessels; 2017 Nov; 32(11):1304-1313. PubMed ID: 28567553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.